These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31463605)

  • 1. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.
    Banks ML
    Handb Exp Pharmacol; 2020; 258():147-165. PubMed ID: 31463605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.
    Karkhanis A; Holleran KM; Jones SR
    Int Rev Neurobiol; 2017; 136():53-88. PubMed ID: 29056156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
    Sirohi S; Aldrich JV; Walker BM
    Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.
    Anderson RI; Becker HC
    Alcohol Clin Exp Res; 2017 Aug; 41(8):1402-1418. PubMed ID: 28425121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.
    Reed B; Butelman ER; Kreek MJ
    Handb Exp Pharmacol; 2022; 271():473-491. PubMed ID: 33174064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the kappa opioid receptor system in opioid use.
    Cayir S; Zhornitsky S; Barzegary A; Sotomayor-Carreño E; Sarfo-Ansah W; Funaro MC; Matuskey D; Angarita G
    Neurosci Biobehav Rev; 2024 Jul; 162():105713. PubMed ID: 38733895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
    Carlezon WA; Krystal AD
    Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
    Nygard SK; Hourguettes NJ; Sobczak GG; Carlezon WA; Bruchas MR
    J Neurosci; 2016 Sep; 36(38):9937-48. PubMed ID: 27656031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.
    Banks ML
    Ann N Y Acad Sci; 2017 Apr; 1394(1):92-105. PubMed ID: 27936284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.
    Erikson CM; Wei G; Walker BM
    Neuropharmacology; 2018 Sep; 140():162-173. PubMed ID: 30075159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.
    Wee S; Koob GF
    Psychopharmacology (Berl); 2010 Jun; 210(2):121-35. PubMed ID: 20352414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study.
    Martinez D; Slifstein M; Matuskey D; Nabulsi N; Zheng MQ; Lin SF; Ropchan J; Urban N; Grassetti A; Chang D; Salling M; Foltin R; Carson RE; Huang Y
    Neuropsychopharmacology; 2019 Sep; 44(10):1720-1727. PubMed ID: 31026862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.
    Banks ML; Hutsell BA; Schwienteck KL; Negus SS
    Curr Treat Options Psychiatry; 2015 Jun; 2(2):136-150. PubMed ID: 26009706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys.
    Hutsell BA; Cheng K; Rice KC; Negus SS; Banks ML
    Addict Biol; 2016 Mar; 21(2):360-73. PubMed ID: 25581305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.
    Clark SD
    Handb Exp Pharmacol; 2022; 271():525-546. PubMed ID: 33459877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights from Preclinical Choice Models on Treating Drug Addiction.
    Banks ML; Negus SS
    Trends Pharmacol Sci; 2017 Feb; 38(2):181-194. PubMed ID: 27916279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.
    Mitchell JM; Liang MT; Fields HL
    Psychopharmacology (Berl); 2005 Nov; 182(3):384-92. PubMed ID: 16001119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
    Browne CA; Wulf H; Lucki I
    Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynorphin activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus.
    Chen Z; Tang Y; Tao H; Li C; Zhang X; Liu Y
    Neuropharmacology; 2015 Oct; 97():259-69. PubMed ID: 26056031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.